OPKO Health Inc

OPK is in a Stage 2 advancing uptrend with a primary Bearish Exhaustion pattern signaling seller fatigue and a likely bottoming bounce. Price is currently pulling back into rising 9- and 20-day EMAs on neutral RSI and moderate volume, offering a high-selectivity speculative entry. With no mean-reversion override, the medium-term bias remains bullish, and buying now into this pullback aligns with the speculative strategy’s emphasis on clear structural support.

• ↑Ended Q2 with $300M+ cash cushioning operations and R&D
• ↑Raised full-year revenue outlook to $560–585M, up from prior
• ↓Diagnostics revenue fell to $74.5M in Q2 from $101.1M prior year